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Matthew J. Kobe‡, David B. Neau§, Caitlin E. Mitchell‡1, Sue G. Bartlett‡, and Marcia E. Newcomer‡2
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Collaborative Access Team, Argonne National Laboratory, Argonne, Illinois 60439
Background: 15-Lipoxygenase-2 is linked to atherosclerotic plaque formation; the homologous enzyme 5-lipoxygenase
initiates the synthesis of proinflammatory leukotrienes.
Results: We determined the crystal structure of 15-LOX-2 in the presence of a substrate mimic.
Conclusion: 15-Lipoxygenase-2 and 5-lipoxgenase display active site variations that confer distinct product specificities.
Significance: These differences can be exploited for the design of isoform-specific anti-inflammatories.
Atherosclerosis is associated with chronic inflammation
occurring over decades. The enzyme 15-lipoxygenase-2 (15LOX-2) is highly expressed in large atherosclerotic plaques, and
its activity has been linked to the progression of macrophages to
the lipid-laden foam cells present in atherosclerotic plaques. We
report here the crystal structure of human 15-LOX-2 in complex
with an inhibitor that appears to bind as a substrate mimic.
15-LOX-2 contains a long loop, composed of hydrophobic
amino acids, which projects from the amino-terminal membrane-binding domain. The loop is flanked by two Ca2ⴙ-binding
sites that confer Ca2ⴙ-dependent membrane binding. A comparison of the human 15-LOX-2 and 5-LOX structures reveals
similarities at the active sites, as well striking differences that
can be exploited for design of isoform-selective inhibitors.

Atherosclerosis is one of several pathologies attributed to an
unchecked inflammatory response. A hallmark of the disease is
the deposition of macrophage-derived foam cells in plaques
that grow to restrict vascular blood flow or rupture. Either
event can culminate in one of the various manifestations of
cardiovascular disease such as heart attack or stroke. A critical
component in the development of atherosclerosis is transformation of macrophages to foam cells, a process involving the
uptake of lipids carried by low-density lipoprotein LDL. The
presence of oxidized lipids in the LDL particles further exacerbates the process by provoking the release of inflammatory
cytokines, attracting still more macrophages to the growing
lesion. Mitigation of this inflammatory response can slow the
progression of atherosclerosis.
The enzyme 15-lipoxygenase (15-LOX),3 which is expressed
in macrophages, has been linked to elevated levels of oxidized
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lipids through several experimental approaches that include
the heterologous expression of human 15-LOX in a mouse
model of hyperlipidemia (1) and pharmacological inhibition of
15-LOX activity (2, 3). Humans have two 15-LOX (4), designated types 1 (ALOX15A) or 2 (ALOX15B), and the type 1
isoform was the form used in the heterologous expression studies cited above. Mouse knock-out studies with the LOX homologue of 15-LOX-1 support a role for ALOX15A in plaque formation (5). However, it is ALOX15B mRNA that is present in
human macrophages (6, 7) isolated from atherosclerotic
plaques. Furthermore, elevated levels of ALOX15B mRNA are
present in carotid lesions derived from symptomatic, rather
than asymptomatic, subjects. ALOX15A mRNA is not detected
above control levels in either case (6). More recently, Magnusson et al. (8) demonstrated that silencing production of the
ALOX15B protein in human macrophages decreased cellular lipid
accumulation, the precipitating factor in foam cell formation.
Finally, 15S-hydroxyeicosatetraenoic acid (HETE), derived
through non-enzymatic reduction of the product of the
15-LOX reaction, has been shown to promote formation of atherosclerotic lesions in a mouse model system (9).
Lipoxygenases (LOX) are a family of iron enzymes that catalyze the peroxidation of polyunsaturated fatty acids to generate
oxylipins, which in both animals and plants serve essential roles
in signaling (10). The reaction proceeds via abstraction of the
hydrogen from the central carbon of a pentadiene and oxidation of the free radical generated two carbons removed from the
site of attack. Six distinct LOX have been identified in mammals
(4), and the enzymes are named according to their product
specificities. Thus, 15-LOX converts the common substrate
arachidonic acid (AA) to 15-hydroperoxyeicosatetraenoic acid
(HPETE) by attack at C13 of AA, whereas 5-LOX attacks at C7
to transform AA to 5-HPETE (and, subsequently, 5-HPETE to
inflammatory leukotriene A4). The question of how the AAmetabolizing enzymes are able to discriminate among the three
chemically equivalent pentadienes of AA to generate a specific
HPETE isomer remains to be clarified.
The various lipid mediators of the cyclooxygenase pathway
can have opposing functions. Similarly, the LOX pathways produce either pro- or anti-inflammatory compounds. For example, 5-LOX alone is responsible for the synthesis of the proin-
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flammatory leukotrienes, but anti-inflammatory lipoxins can
be synthesized by the combined activities of 15- and 5-LOX or
5- and 12-S-LOX. In addition, 15-LOX also synthesizes the
anti-inflammatory neuroprotectin D1 from docosahexaenoic
acid (11). These disparate roles for LOX products make development of isoform-specific LOX inhibitors critical in the quest
for novel therapeutics.
LOX structures share the common framework established by
Boyington et al. (12) with the soybean LOX structure. The animal enzymes, which generally metabolize AA rather than linoleic acid or linolenic acid, represent a pared down version of the
fold, as they are ⬃650 amino acids in length rather than ⬃950
amino acids. However, both the plant and animal enzymes contain an N-terminal membrane binding domain and a C-terminal catalytic domain.
We report here the crystal structure of human 15-LOX-2 in
complex with a competitive inhibitor that appears to bind as a
substrate mimic. This structure reveals a putative membrane
insertion loop and two Ca2⫹-binding sites also found at the
equivalent positions in 5-LOX. Site-directed mutagenesis supports a role for the Ca2⫹-binding sites in membrane binding,
and the unique membrane insertion loop is poised to play a role
in tethering the enzyme at the bilayer. Moreover, a comparison
of human 15-LOX-2 and 5-LOX structures reveals significant
differences in the highly conserved active sites that can be
exploited for isoform-specific inhibitor design.

EXPERIMENTAL PROCEDURES
Plasmid Construction and Protein Expression—15-LOX-2
was co-expressed in Rossetta 2 (DE3) cells in pET Duet-1 with
Escherichia coli yjgD protein. The yjgD gene was amplified from
E. coli DNA and cloned behind promoter 2 in pET Duet-1 by
digesting both vector and insert with NdeI and XhoI. The
human 15-LOX-2 cDNA obtained from the ATCC was amplified with primers containing SpeI and HindIII sites and cloned
behind promoter 1 by digesting the vector with XbaI and
HindIII. After transformation, Rosetta2 cells (Novagen) were
grown as overnight cultures and then diluted (1:100) into 500
ml volumes of Terrific broth (Alpha Biosciences) in 2-liter
Erlenmeyer flasks. After 4 h at 37 °C and 220 rpm, the speed was
reduced to 150 rpm, and the cells were incubated an additional
27 h at 20 °C for leaky expression of 15-LOX-2. Cells were harvested, pelleted, and stored at ⫺80 °C.
Protein Purification—Cells were lysed in a mixture of Bugbuster (Invitrogen) and Problock 2D protease inhibitor mixture
(Gold Biotechnology); both were used according to the manufacturer’s instructions. DNase I (0.2 mg/ml) (Sigma) was
added, and the suspension was processed in a French pressure
cell. Insoluble material was removed by centrifugation at 17,500
rpm for 30 min, and imidazole buffer was added to the supernatant to a final concentration of 20 mM. The sample was
syringe-filtered (0.45 M pore size) and applied to a Co2⫹-nitroloacetic acid column (Pierce) equilibrated with buffer A (20
mM Tris-HCl, pH 8.0, 20 mM imidazole, 500 mM NaCl) and
configured on an Akta FPLC (GE Healthcare). Protein was
eluted with a 0 –100% gradient of buffer B (20 mM Tris-HCl, pH
8.0, 200 mM imidazole, 500 mM NaCl). The major peak eluted
from the column at ⬃30% B. Peak fractions were pooled and
MARCH 21, 2014 • VOLUME 289 • NUMBER 12

concentrated with a 35-kDa Amicon ultra centrifugal filtration
unit (Sigma) and subsequently applied to Superdex 200 (GE
Healthcare) for gel filtration. SDS-PAGE, enzyme assays, and
product analysis confirmed that the major peak which eluted at
86 ml corresponded to 15-LOX-2. Protein was concentrated to
⬃10 mg/ml, flash-frozen dropwise in liquid N2, and stored at
⫺80 °C until use.
Crystallization—15-LOX-2 was screened for crystallization
conditions with crystal screens from Hampton and a Gryphon
liquid dispenser (ARI). Conditions yielding crystalline-like
material were further screened varying pH, buffer, cryo-protectant, and detergent. After extensive additive screening, the
detergent octyltetraethylene glycol ether (C8E4, Anatrace)
proved essential for crystallization. The conditions that yielded
diffraction quality rhombohedral crystals were 1 M NH4SO4, 0.1
M Bis-Tris, pH 5.5, 5% glycerol, and 24 mM C8E4. Crystals were
grown in hanging drops.
Diffraction Data Collection—15-LOX-2 crystals were looped
from the mother liquor and placed directly in the 100 K N2
stream of an Oxford CryoJet or plunged into liquid N2 for shipping. Two x-ray data sets were collected at separate beamlines.
The first data set was collected to a resolution of 2.85 Å at the
Gulf Coast Protein Crystallography Consortium beamline at
the Center for Advanced Microstructures and Devices (Baton
Rouge, LA). The final data set was collected to 2.65 Å at the
24ID-E beamline of the Northeastern Collaborative Access
Team at the Advanced Photon Source (Argonne National Laboratory). This last data set was obtained from a crystal soaked
for 30 min in mother liquor supplemented with 40 mM CaCl2
prior to flash-cooling in liquid N2. HKL2000 (13) was used to
process data collected at the Gulf Coast Protein Crystallography Consortium beamline. XDS, pointless, and scala were used
via the RAPD processing suite of the Northeastern Collaborative Access team to process the data collected by the Northeastern Collaborative Access Team.
The Phenix program suite (14) was used to perform molecular replacement (with PHASER) and the model refinement
that followed. Model building was performed in Coot (15). The
structure of Stable-5- LOX (Protein Data Bank 3O8Y) served as
the search model for the 2.85 Å data set. The model constructed
with this data set was subsequently used as the search model for
the 2.65 Å data from a CaCl2 soaked crystal. Refinement was
performed with Phenix.refine.
Enzyme Assays—Enzyme activity was monitored in an
Applied Photophysics Model SX.18MV stopped-flow spectrometer at 22 °C. Product (15-hydroperoxyeicosatetraenoic
acid) formation was monitored at 235 nm with a cell path length
of 0.2 cm. The enzyme concentration was 60 nm in 20 mM
Tris-HCl (pH 7.5), 150 mM NaCl. Assays were performed with
arachidonic acid (Cayman Chemical) concentrations ranging
from 1 to 40 M. The reported concentrations of reagents are
those in the observation cell. Each kinetic trace was the average
of at least three individual measurements. Km and Vmax value
were determined by non-linear regression analysis of a plot of
velocity versus substrate concentration to Equation 1. Vmax is
the maximal velocity, S is the substrate concentration, and Km is
the Michaelis constant.
JOURNAL OF BIOLOGICAL CHEMISTRY
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⫽

V max ⫻ 关S兴
Km ⫹ 关S兴

(Eq. 1)

Kinetic assays in the presence of C8E4 were performed to determine the mode of inhibition. In these assays, the concentration
of AA was varied between 1– 40 M in the presence of varying
concentrations of C8E4 detergent. The enzyme concentration
was 100 nM. Nonlinear regression was used to analyze the
stopped-flow data (16) obtained as described above. Each data
point is the average of at least three kinetic traces. The data
were fit to Equation 2, where v is the initial velocity, Vmax is the
maximal velocity, S is the substrate concentration, Km is the
Michaelis constant, [I[ is the inhibitor concentration, and Ki is
the inhibition constant.

⫽

V max ⫻ 关S兴
关I兴
⫹ 关S兴
Km 1 ⫹
Ki

冉 冊

(Eq. 2)

Nanodisc Preparation—Nanodiscs were prepared with
MSP1E3D1 and phospholipids as described (17, 18) with minor
modifications. Briefly, plasmid pMSP1E3D1 (Addgene) was
expressed in Rosetta 2 cells in Terrific broth (37 °C) in the presence of 30 g/ml kanamycin. Expression was induced with 0.5
mM isopropyl 1-thio-␤-D-galactopyranoside at A600 of 1.4, and
the cells were allowed to grow for 3.5 h. The temperature was
lowered to 28 °C 1 h post induction. Cells were pelleted and
lysed by sonication in 50 mM sodium phosphate (7.4), 1 mM
PMSF, 1% Triton X-100. Cell debris was pelleted, and the lysate
was applied to a nickel chelate affinity column. The column was
washed with five volumes of 1) buffer C (40 mM Tris (pH 8.0),
300 mM NaCl); 2) plus 1% Triton X-100; 3) plus 50 mM cholate;
4) buffer C, and 5) plus 50 mM imidazole. Protein was eluted
with buffer C containing 300 mM imidazole. MSP1E3D1-containing fractions were pooled, concentrated to at least 5 mg/ml,
dialyzed into nanodisc buffer (20 mM Tris-HCl, pH 7.4, 150 mM
NaCl, 0.5 mM EDTA), and lyophilized.
Nanodiscs were prepared from rehydrated MSP aliquots,
and phospholipids were resuspended in nanodisc buffer containing 100 mM cholate. Mixtures of phospholipids (3:1 porcine
brain PC, porcine brain PS, Avanti Polar Lipids) and MSP
(160:1) in nanodisc buffer with 25 mM cholate were incubated
for 15 min at room temperature. Cholate removal to induce
nanodisc formation was accomplished with the addition of
Biobeads (0.8 g/ml, Bio-Rad) and incubation at room temperature for 2 h. Biobeads were removed by centrifugation. Nanodisc formation and nanodisc binding by 15-LOX-2 were monitored by size exclusion chromatography on a Superose-12
column (GE Healthcare).

RESULTS
A Unique ␤-Hairpin Structure Projects from the Membranebinding Domain—The crystal structure of human 15-LOX-2
was determined at 2.65 Å resolution (Rwork/Rfree ⫽ 16.3/20.3;
Table 1). As expected, 15-LOX-2 displays the typical LOX fold
(Fig. 1, A and B): an amino-terminal ␤-barrel domain, which is
known as a PLAT domain (polycystin-1-lipoxygenase ␣-toxin),
and a significantly larger ␣-helical catalytic domain. The cata-
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TABLE 1
Diffraction data and structure refinement

Data collection
Space group
Cell dimensions
Wavelength
Resolution (Å)
Rmerge
I/I
Completeness (%)
Redundancy
Refinement
Resolution (Å)
No. reflections
Rwork/Rfree
No. atoms
Protein
Water
Iron
Calcium
Ligand (C8E4)
B-factors (Å2)
Protein
C8E4
Calcium
Iron
Solvent
Wilson B
r.m.s.d.a
Bond lengths (Å)
Bond angles
Ramachandran
Outliers (%)
Favored (%)
a

15-LOX-2 (Protein
Data Bank code 4NRE)
(40 mM CaCl2 soak)

15-LOX-2

R32
a ⫽ 155.79, b ⫽ 155.79, and
c ⫽ 263.21 Å; ␣ ⫽ 90,
␤ ⫽ 90, and ␥ ⫽ 120°
0.97923
38.95–2.63 ( 2.72–2.63)
0.048 (0.39)
14.2 (2.0)
94.07 (68.7)
2.6 (2.1)

R32
a ⫽ 154.6, b ⫽ 154.6,
c ⫽ 262.78 Å; ␣ ⫽ 90,
␤ ⫽ 90, ␥ ⫽ 120°
1.38079
50.0–2.72 (2.83–2.72)
0.20 (0.55)
11.95 (1.9)
99.9 (100)
4.9 (4.7)

38.95–2.63 (2.72–2.63)
34,565 (2409)
16.27/20.33 (26.66/29.94)
5882
5385
368
1
2
12
61.6
56.6
75.6
47.4
57.2
50.5
0.005
0.9°
0.0
97

r.m.s.d., root mean square deviation.

FIGURE 1. Overlay of 15-LOX-2 and stable 5-LOX. A, schematic renderings
of 15-LOX-2 (green) and stable 5-LOX (pink). Ca2⫹ is shown as blue spheres, and
the catalytic iron is in rust. B, detail of the difference in positioning of helix ␣2.
Side chains from the 5-LOX segment occupy the shallower half of the
15-LOX-2 inhibitor binding site.

lytic iron is positioned by the side chains of three invariant
histidines (at positions 373, 378, and 553) and the main chain
carboxyl of the C terminus (Ile676). Human 15-LOX-2 shares
42% sequence identity with human 5-LOX and 38% or less than
that with any other LOX for which a structure has been
reported (19 –24).
VOLUME 289 • NUMBER 12 • MARCH 21, 2014
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TABLE 2
15-LOX-2 kinetic parameters

FIGURE 2. 15-LOX-2 and membrane binding. A, surface rendering of
15-LOX-2. The putative membrane insertion loop projects from the aminoterminal PLAT domain; prolines present in the loop are colored in red. B, rotation 90° about the horizontal, looking into the active site (C8E4, teal). The
Ca2⫹-binding sites (blue spheres) are on the same face of the molecule as the
active site cavity, which is open to solvent. C, upper panel: in the presence of
Ca2⫹, 15-LOX-2 co-elutes with nanodiscs. Dashed line, 0.5 mM EDTA; solid lines,
plus 2 mM CaCl2. Blue, wild-type; red, D39A/E44A; gray, D39A/E44A/D85A.
Lower panel: for reference, individual elution profiles for nanodiscs (ND; black)
and 15-LOX-2 (blue); dashed line, 0.5 mM EDTA; solid line, plus 2.0 mM Ca2⫹. D,
detail of the Ca2⫹-binding site that anchors the insertion loop. Three main
chain carbonyls, Asp85, and water (red spheres) coordinate the Ca2⫹ (blue
spheres).

LOXs are cylindrical in overall shape (⬃100 Å in length, ⬃45
Å in width), and the PLAT domain is roughly one-third of the
cylinder. In 15-LOX-2, the PLAT domain contains two apparent Ca2⫹-binding sites, the first of which (Ca-l) is located in the
turn at amino acids 39 – 44. The Ca2⫹ in Ca-1 is coordinated by
Asp39 and Glu44 and the main chain carbonyls of Asn40 and
Gly42 and a water molecule. The second site (Ca-2) appears to
stabilize an ⬃12-amino acid loop at Pro74–Ala86 that connects
strands from the two sides of the stacked ␤-sheets of the barrel.
This proline-rich hydrophobic loop projects 20 Å from the
membrane-binding domain as a hairpin-like structure. The
Ca-2 site, which is coordinated by Asp85, the main chain carbonyls of Ala86, Gly15, Gly17, and a water molecule, appears to
anchor the C-terminal region of the hairpin loop. The loop is
restrained by a crystal-packing contact in the crystal structure,
as it is nestled at the active site entrance of a neighboring molecule. Although this interaction may constrain the loop in an
extended fashion, the prolines at its base and within the
sequence also provide rigidity and contribute to its projection
from the body of the protein. The projection of the loop from
the body of the protein is visible in the surface rendering in Fig.
2, A and B.
Phospholipase A2 and human 5-LOX contain highly conserved calcium binding sites in their PLAT domains (13, 19, 20).
Although sequence homology is low, the 15-LOX-2 Ca-1 and
Ca-2 binding sites are in equivalent positions with those in
5-LOX, which displays Ca2⫹-dependent membrane binding
(25, 26). The Ca2⫹-binding sites are positioned along one edge
of the PLAT domain, on the same face of the elongated molecule that harbors the entrance to the catalytic site. These obserMARCH 21, 2014 • VOLUME 289 • NUMBER 12

Enzyme

Km

kcat

M

s⫺1

Wild type
D39A/E44A
D39A: D3
D39A/E44A/D85A

1.9 ⫾ 0.37
1.7 ⫾ 0.16

0.6 ⫾ 0.02
0.5 ⫾ 0.01

0.76 ⫾ 0.06

0.6 ⫾ 0.01

vations led us to test whether Asp39, Glu44, and Asp85 confer
Ca2⫹-dependent membrane binding of 15-LOX-2 (27).
Ca2⫹-dependent Membrane Binding—Ca2⫹-dependent
membrane binding was monitored using nanodiscs as membrane mimics. Nanodiscs with a diameter of ⬃110 Å were prepared with membrane scaffold protein E3. In the absence and
presence of Ca2⫹ nanodiscs and 15-LOX-2 elute at ⬃9.7 and
⬃11.2 ml, respectively, on a Superose 12 column (Fig. 2C). In
the absence of Ca2⫹, when co-incubated mixtures are applied
to the sizing column, nanodiscs, and 15-LOX-2 retain their
individual elution volumes. In contrast, with the addition of 2
mM CaCl2 to the elution buffer (which is 0.5 mM EDTA), the
LOX peak shifts to indicate co-elution with nanodiscs. This
same shift was observed in a mutant that lacks Ca-1 (D39A/
E44A). In contrast, a mutant lacking both calcium sites (D39A/
E44A/D85A) eluted at a volume consistent with free enzyme
(Fig. 2C). Mutations of Ca2⫹-binding amino acids does not significantly affect enzyme activity (Table 2). All enzymes display
the same kcat, an indication that the catalytic machinery
remains intact. A detail of the Ca-2 site, which anchors the
extended loop, is depicted in Fig. 2D.
The Crystal Structure of 15-LOX-2 Reveals a Novel Inhibitor
Binding in a Substrate-like Conformation—The LOX catalytic
domain is a bundle of ⬃20 helices. Although LOXs share a
common fold and the conformations and placement of the
majority of the helices are conserved, two distinct configurations have been described for the region that constitutes the
second helix (␣2) in this domain (amino acids 178 –199 in
15-LOX-2). In 15-LOX-1 (20), 8R-LOX (23) and 12-LOX (21),
this region is a single ␣-helix that extends nearly the length
of the catalytic domain and rims the active site cavity. In contrast, the same segment in the 5-LOX (19) and 11R-LOX (22)
structures is a meandering, broken helix that seals off the cavity.
The structure of human 15-LOX-2 displays the first orientation: a single ␣-helix that helps define the periphery of the
active site (see Fig. 1). The opposite rim of the active site is
formed by a structurally conserved “arched” helix (amino acids
410 – 430 in 15-LOX-2).
In the first experimental map calculated with data to 2.8 Å
resolution, a continuous electron density that could not be
attributed to polypeptide was positioned above the catalytic
iron. The polyoxyethylene detergent C8E4, which was required
for diffraction quality crystals, was the most likely candidate for
this density. A molecule of C8E4 was fit into the density such
that the polyoxyethylene tail was innermost and the hydrocarbon end made its way out of the active site through the entrance
portal defined by ␣2 and the arched helix (Fig. 3A). The higher
sigma value of the innermost electron density most likely represents the O-rich end of the detergent, but it is not possible to
definitively determine the orientation of C8E4 in the active site.
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 3. The structure was determined in the presence of a competitive inhibitor. A, omit map (calculated without C8E4) electron density (2Fo ⫺ Fc, 1)
positioned above the active site iron is consistent with the detergent C8E4. B, the amino acids that line the active site cavity. Shown is atomic coloring (green,
carbon; red, oxygen; blue, nitrogen), with invariant/highly-conserved amino acids in gray. C, non-linear regression analysis of enzyme activity measured at
varying inhibitor and substrate concentrations. (⽧, 0 mM; E, 0.1 mM; , 1.0 mM C8E4; AA from 1 to 40 M). The points represent the observed velocities, and the
lines represent the best fit of the data to Equation 2. D, AA (purple and yellow stick renderings; red, oxygen) can be modeled into the C8E4 density in two inversely
related orientations. E, detail of the placement of the yellow AA in D. The iron (rust) coordination sphere is filled by His-373, His-378, His-553, the carboxyl
terminus, and two water molecules (red). The hydrogen of the pentadiene is poised for abstraction. The asterisk marks C13. The inverse fit of AA C7 sits at this
position.

(The Protein Data Bank file contains a second detergent modeled on the surface of the protein. Based on the paucity of contacts it makes with the protein and the high concentration of
detergent in the crystallization buffer, this is likely a nonspecific
protein-detergent interaction.)
The active site C8E4 sits in the cavity in a U-shaped conformation and is surrounded primarily by the side chains of hydrophobic amino acids (Fig. 3B). Proximal to the base of the “U” sits
the catalytic iron, held in place by invariant histidines 373, 378,
and 553. Given the shape of the cavity, we asked whether C8E4
might mimic the conformation of the natural substrate AA and
serve as a competitive inhibitor. To test this hypothesis, enzyme
activity was assayed by monitoring the increase in absorbance
(235 nm) of HPETE at varying C8E4 concentrations. The data
were fit to Equation 2. Non-linear regression analysis by the
method of Cleland (16) indicates the Ki for C8E4 is 92 (⫾16) M
(Fig. 3C), and the inhibition is competitive. In contrast, a satisfactory fit to the equation for non-competitive inhibition was
not obtainable.
Modeling of AA in the Active Site—Given that C8E4 competitively inhibits 15-LOX-2, we asked whether the substrate
might fit into the volume occupied by the detergent. Two orientations are possible: one with the carboxyl (“head”) innermost and the other the hydrocarbon (“tail”) end innermost. We
refined both orientations in the C8E4 electron density with the

8566 JOURNAL OF BIOLOGICAL CHEMISTRY

refine ligand option in PHENIX. As can be seen from Fig. 3D,
both fit into the C8E4 density, suggesting that the detergent
bound structure is similar to that of the substrate-bound
structure.
Mechanistic studies have demonstrated that abstraction of
the hydrogen from the central carbon of the pentadiene and
oxidation occur on opposite faces of the AA (see Ref. 28). LOX
structures provide a framework to envision why this is
necessary, as the same amino acids that position the catalytic
iron shield the pentadiene from molecular oxygen (Fig. 3).
Crystal structures of LOX reveal the enzyme resting state in
which in Fe2⫹ occupies the metal binding site. The enzyme
must be activated to Fe3⫹ to proceed with catalysis as it is
Fe3⫹OH⫺ that abstracts the H from the pentadiene (see Ref.
29). Note that in Fig. 3E, the Fe2⫹ coordination is completed
with two waters. One of these waters is poised to strike a substrate H on the central carbon of the positioned pentadiene
(Fig. 3E). In the “tail first” fit, this is C13, whereas in the head
first orientation, it is C7.
Fig 4, A and B, provides a view of the relative placements of
the substrate binding site, the O2 channel (30), and the catalytic
iron. Although AA can be modeled in two orientations that are
“inversely” related, only one orientation is consistent with the
product specificity of 15-LOX-2. A schematic provided Fig. 4C
summarizes this information. Note the “inverse” orientations
VOLUME 289 • NUMBER 12 • MARCH 21, 2014
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FIGURE 4. Mechanistic details are consistent with a unique orientation of
AA in the active site. A, the contour of the active site with bound C8E4 is
complementary to AA in shape, and the catalytic iron and apparent oxygen
channel lie on opposite sides of the tunnel. This relationship between O2
channel and catalytic iron is shown clearly in B. C, schematic of the two fits
(Fig. 3D) of AA. The substrate can be modeled it with its tail (top) or head
deepest in the cavity (bottom). The depth of the pocket and the orientation of
the substrate determine which pentadiene is positioned for attack. In the top
orientation, the pentadiene at C13 is positioned for attack; in the lower, C7 is
positioned proximal to the red sphere (iron) behind the plane. The blue peanut
represents the O2 channel slightly deeper in the active site but above the
plane. A single product is produced by each orientation: with the tail end
innermost AA is transformed to 15-S-HPETE, whereas the inverse orientation
results in 5-S-HPETE.

of AA on the left side of the figure. Both AAs are positioned such
that the iron (red sphere) and O2 channel (blue peanut) are on
opposite sides, but in the upper one, C13 is positioned for attack
and in the lower C7. (It is not possible for either orientation to
slide deeper in the pocket to produce another regiochemistry.)
To produce 15-HPETE, hydrogen abstraction must occur at
C13, which is only possible with tail first entry. Note that
abstraction of the “back” hydrogen dictates oxygenation on the
“front.” The top product is 15-S-HPETE, and the lower product
is 5-S-HEPTE. So the first orientation has both the correct
regio- and stereo-chemistries because 15-LOX-2 generates
15-S-HPETE exclusively. Moreover, 15-LOX-2 can process
phospholipid-esterified AA (31). This observation is not possible if the carboxyl end were innermost in the site because there
is no room for the phospholipid head group.
In conclusion, the detergent defines a cavity that can accommodate AA with no further conformational changes. Moreover, the
substrate pentadiene centered at C13 is positioned for attack. An
O2 channel lies slightly deeper in the cavity to allow O2 access to
C15. The stereochemistry of the product for this model is what is
observed in vivo. The structure is entirely consistent with tail-first
entry, and inconsistent with head-first entry of substrate.

DISCUSSION
Several lines of evidence indicate a link between 15-LOX activity and atherosclerosis. Macrophage uptake of oxidized low-density lipoprotein promotes their progression to lipid-loaded foam
cells that contribute to atherosclerotic plaques, and oxidized lowMARCH 21, 2014 • VOLUME 289 • NUMBER 12

density lipoprotein levels correlate with 15-LOX activity. A model
for how an intracellular enzyme such as 15-LOX can contribute to
the oxidation of extracellular LDL has been proposed by Hutchins
and Murphy (32). The investigators identified 15-LOX products of
the cholesterol esters of deuterated AA and linoleic acid in macrophages incubated with lipid vesicles of cholesterol ester-esterified
arachidonic and linoleic acids. Their results led them to suggest
that the hydroperoxy acid products generated by cytosolic
15-LOX enter into extracellular pools of cholesterol esters and
phospholipids through both the continuous remodeling of cholesterol esters and phospholipids and the constant trafficking of lipids
among cellular compartments.
Two 15-lipoxygenases, with ⬍40% sequence identity and distinct patterns of expression and product profiles, have been
identified in humans (27, 33). Human 15-LOX-1 generates
15-HPETE, and to a lesser extent 12-HPETE using AA as a
substrate, whereas the product of 15-LOX-2 with AA is exclusively 15-HPETE (33). Recent data implicate the 15-LOX-2 isoform in the pathogenesis of atherosclerosis because mRNA and
protein levels of this LOX have been shown to be high in
human carotid plaques (6). In addition, 15-LOX-2 is
expressed in macrophages (7, 34, 35), and expression is regulated by hypoxia-inducible factor-1␣ (35). Moreover, knockdown of 15-LOX-2 expression in human primary macrophages
and in mice (in this case, the target was 8-LOX, the murine
homologue of 15-LOX-2) decreased lipid accumulation and
inflammation, hallmarks of atherosclerosis (8).
Our 15-LOX-2 structure revealed a hydrophobic hairpin structure that projects from the amino-terminal membrane binding
domain. Sequence alignment indicates that this hairpin is unique
to the 15-LOX-2 isoform and could help position the enzyme at
the phospholipid bilayer. Unlike 5-LOX, 15-LOX-2 can process
PC-esterified AA (31). This activity suggests a model in which
translocation to the membrane increases accessibility to substrate
and a tethered enzyme could function at the membrane interface
for utilization of AA-bearing phospholipids without the need for a
lipase, or for re-esterfication of the product for the oxidized product to enter the PL trafficking pathways.
Structures for two mammalian homologues of 15-LOX-1
(⬎80% identity to human 15-LOX-1, but ⬍40% to 15-LOX-2)
have been reported: one is in the absence and presence of inhibitor (20), and the other is the catalytic domain only with inhibitor (21). These models serve as reliable templates for human
15-LOX-1. The structures of the two 15-LOX isoforms are
essentially the same in terms of overall fold: 15-LOX-2 superimposes with the porcine homologue with an rmsd of 1.62 Å
(552 C␣) and with the uninhibited rabbit 15-LOX-1 with an
rmsd of 1.9 Å (667 C␣). However, 15-LOX-1 lacks the extended
loop at amino acids 73– 85 of 15-LOX-2.
The 15-LOX-2 Inhibitor Defines the Substrate-bound
Conformation—Recall that kinetic data indicate that C8E4 is a
competitive inhibitor. In addition, AA can adopt an equivalent
U-shaped conformation to that of the bound detergent. Moreover, placement of AA tail-first in the C8E4 electron density
positions the pentadiene centered at C13 for attack (Fig. 3, D
and E). This positioning would generate the 15-S product, consistent with the product stereochemistry observed for both
15-LOX isoforms. Furthermore, a channel that would allow the
JOURNAL OF BIOLOGICAL CHEMISTRY

8567

The Structure of 15-Lipoxygenase-2
approach of O2 to the activated pentadiene (30) is clearly visible
in the surface rendering in Fig. 4. The competitive inhibitor
included in the porcine structure indicates a similar, but slightly
deeper, cavity to allow three more carbons past that catalytic
iron and attack at C10 (the porcine homologue generates
12-HPETE and attacks at C10). In contrast, the rabbit 15-LOX
structure with inhibitor displays a striking conformational
change with ⬃10 Å displacement of helix ␣-2 that likely is
unique to the inhibitor included in the crystallization, a conformationally restrained compound that makes contacts inconsistent with the native substrate. Consequently, the 15-LOX-1:
inhibitor structure provides solid evidence for malleability of
these active sites, and binding site plasticity expands opportunities for isoform-specific inhibitor development.
15-LOX-2 and 5-LOX Differ in the Orientations of Their
Common Substrate—The two structures of human LOX now
available, the 15-LOX-2 described here and stable 5-LOX (19), can
help to formulate novel strategies toward the development of isoform-specific inhibitors because the enzymes display distinctly different active site cavities. A major difference between the two is
that the 5-LOX cavity is sealed off by the atypical placement of ␣2,
whereas that in 15-LOX-2 is open to solvent. The closest homologue to 15-LOX-2 in humans is 5-LOX. Recall that if AA were
positioned head-first in the 15-LOX-2 active site, it would be
transformed to 5-S-HPETE, the 5-LOX product. Extensive biochemical studies have led to a model in which both cavity depth
and head versus tail entry of AA combine to explain the varying
regio- and stereo-isomer specificities of LOX family members (28).
This model predicts that AA enters 5-LOX head-first. We asked
whether the head-first entry of AA in 15-LOX-2 as illustrated in
Fig. 4C (bottom) might provide insight into how AA binds in
5-LOX. The images and schematic in Fig. 5 reveal that although
the internal portions of the LOX cavities are similar in volume,
they have dissimilar chemistries. Note that with the loss of a Glu,
and the gain of 2 His, the inner portion of the 5-LOX cavity is more
positive in overall change. The amino acids that hold the catalytic
iron in place and position the pentadiene for attack are common to
both active sites and composed of invariant or highly conserved
amino acids. It is not possible to compare the cavities at the carboxyl end of the 15-LOX-2 active site because this end is tightly
corked by Phe177 and Tyr181 in 5-LOX. Although it is tempting to
speculate that this end of the site must uncork for AA to enter the
5-LOX active site, these experiments are beyond the scope of this
work.
The Murine Homologue of 15-LOX-2 Is an 8-LOX—15-SHETE (generated by non-enzymatic reduction of 15-S-HPETE)
has been shown to be the LOX product that contributes to
atherosclerosis in a murine model system (9). However, silencing expression of murine ALOX15B (which produces 8-HPETE
from AA rather than 15-HPETE) mitigated plaque formation
(8). These studies appear to be at odds: the former indicates that
it is the product of a 15-LOX that promotes plaque formation,
whereas one might infer from the latter studies that 8-HETE
should be the proinflammatory lipid mediator in the mouse
model. This apparent contradiction can be reconciled. Again,
the model that proposes that LOX enzymes can differ in terms
of whether AA enters head- or tail-first (28) is invoked here.
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FIGURE 5. The substrate binding cavities of 15-LOX-2 and stable 5-LOX. A,
a surface rendering of the inhibitor binding site in 15-LOX-2 reveals a cavity
that can accommodate AA. The catalytic iron is behind the inhibitor (orientation similar to that in Figs. 3A and 4A), and an apparent O2 channel is on the
upper face (29). B, a similar rendering of the cavity in 5-LOX with the 15-LOX-2
inhibitor superimposed. Note that the volumes of the cavities beyond the O2
channel are similar, but that 5-LOX is “corked” above the channel by two
amino acids from ␣2 (Phe177, Tyr181). C, schematic of inverse orientations of
AA (black, tail first). Amino acids that line the cavity in 15-LOX-2 are listed with
5-LOX counterparts in parentheses. Invariant amino acids are in boldface type.
Amino acid changes that result in an increase in positive change deep in the
cavity of 5-LOX are highlighted in blue.

Jisaka et al. (36) demonstrated that the difference in products
of 15-LOX-2 and its murine counterpart 8-LOX (87% sequence
identity) can be explained by the substitution of Asp602/Val603
with Tyr/His at the equivalent positions in the 8S-enzyme.
Val603 is deep in the 15-LOX-2 cavity (Fig. 3B) where the hydrocarbon end of the substrate sits, and mutation of the murine
enzyme to the human sequence (a His to Val) at this position
transformed the 8-LOX into a 15-LOX by converting an
enzyme in which AA enters head-first (as in 5-LOX) to one that
enters tail first (as in 15-LOX-2).
Recall that 15-LOX-2 can metabolize PC-esterified AA. It has
been reported that murine 8-LOX can also transform phospholipid-esterified AA (31). However, the presence of the phospholipid
head group makes head-first entry impossible in the 8-LOX active
site, so the murine enzyme cannot produce the 8S isomer from
PC-AA. Instead, with PC-AA as the substrate, the murine 8S-LOX
is forced to accept tail-first entry. Thus with PC-esterified substrate 8-LOX could be a de facto 15-LOX. Given that 15-LOX-2
displays Ca2⫹-dependent membrane binding, and the mouse
homologue includes those amino acids that confer binding and the
putative membrane insertion loop, one might predict that in vivo,
the murine enzyme can generate PC-esterified 15-HPETE that
ultimately enters the cellular pool of free 15-HETE. It is noteworthy that murine 8-LOX is an anomaly because the other ALOX15B
homologues generate 15-HPETE.
Concluding Remarks—In summary, we report here the structure of human 15-LOX-2. As expected 5-LOX and 15-LOX-2
share a common framework, a common catalytic core, and a common substrate. However, the enzymes generate distinct isomers of
the product. A comparison of the structures of active site cavities
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of this pair of enzymes, along with an understanding of catalytic
mechanism, provides insights into substrate recognition.
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